Zacks restated their neutral rating on shares of Hospira (NYSE:HSP) in a research note issued to investors on Wednesday, StockRatingsNetwork.com reports. The firm currently has a $44.00 price target on the stock.
Zacks’ analyst wrote, “Hospira, Inc.’s third quarter 2013 adjusted earnings of $0.51 per share surpassed the Zacks Consensus Estimate by $0.06 and the year-ago earnings by $0.04. Results were aided by lower costs. We are encouraged by the European approval of Inflectra for the treatment of inflammatory conditions. Inflectra is the biosimilar version of Johnson & Johnson/Merck’s Remicade. We are also impressed by Hospira’s efforts to resolve the manufacturing issues confronting it. The upbeat long-term view provided by Hospira at its investor day is encouraging. We believe that the stock is fairly valued at current levels and hence retain our Neutral recommendation on the stock. Our target price is $44.00.”
Shares of Hospira (NYSE:HSP) traded down 0.25% during mid-day trading on Wednesday, hitting $40.41. The stock had a trading volume of 184,789 shares. Hospira has a 1-year low of $28.71 and a 1-year high of $42.60. The stock’s 50-day moving average is $40.00 and its 200-day moving average is $39.20. The company’s market cap is $6.703 billion.
Hospira (NYSE:HSP) last announced its earnings results on Wednesday, November 6th. The company reported $0.51 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.45 by $0.06. The company had revenue of $1,000.00 million for the quarter, compared to the consensus estimate of $992.20 million. During the same quarter last year, the company posted $0.47 earnings per share. Hospira’s revenue was up 1.4% compared to the same quarter last year. Analysts expect that Hospira will post $2.08 EPS for the current fiscal year.
HSP has been the subject of a number of other recent research reports. Analysts at Barclays raised their price target on shares of Hospira from $36.00 to $40.00 in a research note to investors on Thursday, November 7th. They now have an equal weight rating on the stock. Analysts at Guggenheim initiated coverage on shares of Hospira in a research note to investors on Thursday, September 26th. They set a buy rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $37.67.
Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.